ROGAINE EXTRA STRENGTH (FOR MEN)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROGAINE EXTRA STRENGTH (FOR MEN) (ROGAINE EXTRA STRENGTH (FOR MEN)).
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
| Metabolism | Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%). |
| Half-life | Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues. |
| Bioavailability | Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation). |
| Onset of Action | Topical: visible hair regrowth may be observed after 4–6 months of twice-daily application. Maximal response typically requires at least 12 months of continuous use. |
| Duration of Action | Duration of effect is dependent on continued application. Discontinuation results in reversal of hair regrowth within 3–6 months, returning to pretreatment baseline. |
1 mL of 5% minoxidil solution applied topically to the scalp twice daily.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts. |
| Liver impairment | No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts. |
| Pediatric use | Safety and effectiveness in pediatric patients under 18 years have not been established. |
| Geriatric use | No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROGAINE EXTRA STRENGTH (FOR MEN) (ROGAINE EXTRA STRENGTH (FOR MEN)).
| Breastfeeding | Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to minoxidil or any component of the formulation.","Concomitant use with other topical agents on the scalp."]
| Precautions | ["Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.","May cause hypotension if accidentally ingested.","Avoid contact with eyes and broken skin.","Discontinue if scalp irritation occurs.","Use with caution in patients with hypertension or underlying cardiovascular disease."] |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care. Monitor maternal blood pressure if large areas of damaged skin are treated due to potential increased absorption. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies or human data with topical minoxidil. Systemic exposure is minimal and unlikely to affect reproductive function. |